Pulmonary Complications in Candidates for Liver Transplantation

Razavi-Khorasani, Niloofar; Moazzami, Bobak; Moghadam, Arash Dooghaie; Eslami, Pegah; Farokhi, Ermia; Mehrvar, Azim; Saeedi, Sandra; Iravani, Shahrokh; Pasha, Morteza Aghajanpoor; Toosi, Mohsen Nasiri

doi:10.34172/mejdd.2020.176

Cited by 3 publications

(1 citation statement)

References 80 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liver transplantation (LT) has been established as the only viable treatment option for patients with advanced liver cirrhosis. 1 , 2 Hepatitis B virus (HBV) infection is one of the most common etiologies of liver diseases worldwide, which is associated with a wide range of complications. 3 It has been estimated that about 240 million people are affected by this infection globally, and more than 780,000 cases will eventually die every year because of its debilitating complications.…”

Section: Introductionmentioning

confidence: 99%

An Overview of the Current Hepatitis B Treatment Strategies after Liver Transplantation

Moghadam

Eslami

Beirami

et al. 2021

Middle East J Dig Dis

Self Cite

View full text Add to dashboard Cite

Currently, liver transplantation (LT) is considered as the only option for the treatment of patients with various causes of liver failure, including patients with chronic hepatitis B virus (HBV) infections. Overall, patients with HBV who undergo LT are at increased risk of hepatitis B infection recurrence. Although the current knowledge regarding the pathophysiology of this infection has been dramatically increased over the past few decades, it is still considered a complex disease process with varying degrees of clinical characteristics and changing patterns over time. There are various treatment strategies for preventing HBV recurrence in the LT setting. Generally, these regimens include oral nucleoside/ nucleotide analogues (NAs), hepatitis B immune globulin (HBIG), and vaccines or the combination of these drugs. The treatment strategy of choice should be based on costeffectiveness, along with other patients underlying conditions. In this case, studies indicate that potent NAs are more cost-effective than HBIG in most case scenarios. In this article, we aimed to review the general medications used in the prophylaxis of the recurrence of HBV infection after LT.

show abstract

Section: Introductionmentioning

confidence: 99%

An Overview of the Current Hepatitis B Treatment Strategies after Liver Transplantation

Moghadam

Eslami

Beirami

et al. 2021

Middle East J Dig Dis

Self Cite

View full text Add to dashboard Cite

show abstract

Expert consensus on liver transplantation perioperative evaluation and rehabilitation for acute-on-chronic liver failure

Zheng

Liu

et al. 2022

Liver Research

View full text Add to dashboard Cite

Portopulmonary hypertension: peculiarities of diagnosis and treatment

Chooklin,

Chuklin,

Posivnych

et al. 2024

ЕМ

View full text Add to dashboard Cite

Portopulmonary hypertension is defined as the development of pulmonary hypertension secondary to portal one. Its exact prevalence is difficult to determine due to the lack of routine screening in patients with portal hypertension. Hemodynamic changes associated with portal hypertension, including the hyperdynamic state, portosystemic shunts, and splanchnic vasodilation, cause significant disturbances in the pulmonary vasculature and play a key role in the pathogenesis of the disease. Without treatment, portopulmonary hypertension leads to progressive right ventricular failure with a poor prognosis. Although Doppler echocardiography is the best initial screening tool for symptomatic patients and candidates for liver transplant, right heart catheterization remains the gold standard for disease diagnosis. Treatment of patients with portopulmonary hypertension is aimed at improving cardiac function, reducing pulmonary vascular resistance, and optimizing functional capacity. Pulmonary hypertension-specific therapy, which includes prostacyclin and its receptor agonists, endothelin receptor antagonists, phosphodiesterase inhibitors, and guanylate cyclase stimulators, plays a key role in the treatment of patients with portopulmonary hypertension. Small uncontrolled and recent single randomized controlled trials have reported promising results of vasodilator therapy in terms of clinical and hemodynamic improvement in patients, allowing certain patients to undergo liver transplantation. This review discusses the epidemiology, approach to diagnosis and treatment of patients with portopulmonary hypertension. We used MEDLINE database on the PubMed platform and the Cochrane library to search for literature sources using the keywords: portopulmonary hypertension, portal hypertension, pulmonary hypertension, liver cirrhosis, pulmonary complications.

show abstract

Pulmonary Complications in Candidates for Liver Transplantation

Cited by 3 publications

References 80 publications

An Overview of the Current Hepatitis B Treatment Strategies after Liver Transplantation

An Overview of the Current Hepatitis B Treatment Strategies after Liver Transplantation

Expert consensus on liver transplantation perioperative evaluation and rehabilitation for acute-on-chronic liver failure

Portopulmonary hypertension: peculiarities of diagnosis and treatment

Contact Info

Product

Resources

About